MARIA BOTTAZZI to Protozoan Vaccines
This is a "connection" page, showing publications MARIA BOTTAZZI has written about Protozoan Vaccines.
Connection Strength
3.807
-
Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
Score: 0.595
-
Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
Score: 0.527
-
Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
Score: 0.412
-
Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
Score: 0.229
-
ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against Ascaris suum Infection. Front Immunol. 2021; 12:788185.
Score: 0.196
-
Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
Score: 0.192
-
Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
Score: 0.185
-
Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine. 2020 06 15; 38(29):4584-4591.
Score: 0.176
-
A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
Score: 0.164
-
Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Hum Vaccin Immunother. 2019; 15(1):210-219.
Score: 0.157
-
Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
Score: 0.151
-
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
Score: 0.137
-
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016 04 02; 12(4):976-87.
Score: 0.131
-
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
Score: 0.126
-
Limited antigenic variation in the Trypanosoma cruzi candidate vaccine antigen TSA-1. Parasite Immunol. 2014 Dec; 36(12):708-12.
Score: 0.120
-
Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections. Expert Rev Vaccines. 2014 Mar; 13(3):321-31.
Score: 0.113
-
Vaccination of dogs with a recombinant cysteine protease from the intestine of canine hookworms diminishes the fecundity and growth of worms. J Infect Dis. 2004 May 15; 189(10):1952-61.
Score: 0.058
-
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
Score: 0.054
-
Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
Score: 0.048
-
Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
Score: 0.036